Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,799.00-1.71%ETH$2,453.65-0.48%GOLD$4,367.20-0.91%OIL$103.26+0.76%
Smart Investors Daily
IM

NASDAQ · IMNN

Imunon, Inc.

Healthcare · Biotechnology

$1.45

Down-$0.06 (-3.97%)

Updated Sep 11, 2026, 7:52 AM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
10.46M
P/E ratio
-0
Dividend yield
0.00%
52-week range
$1.47 – $3.30
Volume
1.1M
Avg. volume
90.7K

Price performance

IMNN price history

1M range · 20 trading sessions · Daily adjusted prices

IMNN closed at $1.45 after 20 trading sessions, down 8.23% for the selected period.

Last close
$1.45
Period change
-8.23%
Period low
$1.45
Period high
$1.66
Daily close
View OHLC price history
IMNN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$1.65$1.75$1.385$1.451.1M
Sep 9, 2026$1.54$1.5673$1.50$1.5124.42K
Sep 8, 2026$1.56$1.5951$1.53$1.5440.84K
Sep 4, 2026$1.56$1.58$1.54$1.5834.01K
Sep 3, 2026$1.56$1.59$1.5066$1.5619.17K
Sep 2, 2026$1.5987$1.6134$1.51$1.5634.22K
Sep 1, 2026$1.62$1.64$1.56$1.6033.86K
Aug 31, 2026$1.60$1.63$1.55$1.6318.4K
Aug 28, 2026$1.60$1.6469$1.55$1.6082.36K
Aug 27, 2026$1.6045$1.6435$1.55$1.6021.73K
Aug 26, 2026$1.62$1.6598$1.58$1.6348.41K
Aug 25, 2026$1.62$1.70$1.60$1.6686.62K
Aug 24, 2026$1.63$1.6399$1.59$1.5933.05K
Aug 21, 2026$1.61$1.67$1.59$1.6458.86K
Aug 20, 2026$1.62$1.62$1.52$1.58123.55K
Aug 19, 2026$1.58$1.70$1.53$1.58183.83K
Aug 18, 2026$1.61$1.62$1.54$1.5837.72K
Aug 17, 2026$1.64$1.679$1.57$1.6028.14K
Aug 14, 2026$1.58$1.67$1.57$1.6556.77K
Aug 13, 2026$1.61$1.61$1.57$1.5832.77K

Latest IMNN news

The latest Smart Investors Daily articles mentioning IMNN.

Stock researchCompany · Overview

IMNN research

Overview

Company profile and research snapshot.

Company profile

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
IMNN recent ratings
DateFirmRatingTarget
Apr 17, 2026Maxim GroupBuy—
May 19, 2025D. Boral CapitalHold—
May 13, 2025D. Boral CapitalBuy—
May 7, 2025D. Boral CapitalBuy—
Mar 26, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 26, 2026

IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001

Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting science and data, clinical progress, and upcoming milestones A patient treated with IMNN-001 will share firsthand perspective on her treatment journey and life following participation in the clinical trial The event will be held on September 23 in New York City and will be webcast live LAWRENCEVILLE, N.J., Aug. 26, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnolo

Yahoo · Aug 19, 2026

IMNN: Strong Enrollment Momentum Continuing for Phase 3 OVATION 3 Trial

By David Bautz, PhD NASDAQ: IMNN READ THE FULL IMNN RESEARCH REPORT Business Update OVATION 3 Enrollment Runs Ahead of Plan Imunon, Inc. (NASDAQ: IMNN) continues to make progress with the pivotal Phase 3 OVATION 3 study of IMNN-001 in newly diagnosed advanced ovarian cancer. In July, the company reported that enrollment was proceeding at approximately 0.5 patients per site per month, well above

Benzinga · Aug 11, 2026

Imunon Q2 EPS $(0.54) Beats $(0.93) Estimate

Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.93) by 41.94 percent. This is a 74.88 percent increase over losses of $(2.15) per share from the same

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By